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To characterize the cellular density and proliferative activity of 
glial fibrillary acidic protein (GFAP)-negative cells in pilocytic 
astrocytoma (PA), surgically excised tissues of PAs (n=37) and 
diffuse astrocytomas (DAs) (n=11) were examined 
morphologically and immunohistochemically using antibodies 
against GFAP, Olig2, Iba1 and Ki-67 (MIB-1).  In PA, Olig2 
immunoreactivity was significantly expressed in protoplasmic 
astrocytes in microcystic, loose areas and cells in 
oligodendroglioma-like areas.  Iba1-positive, activated 
microglia/macrophages were also commonly observed in 
microcystic areas.  In compact areas, a prominent reaction for 
GFAP was observed, but for Olig2 and Iba1 to a lesser degree.   
On semiquantitative analysis, the number of Olig2-positive cells 
was significantly higher in PAs (mean labeling index (LI) ± 
standard deviation (SD): 46.8 ± 15.4%) than in DAs (13.3 ± 
7.8%) (P<0.001).  Many Iba1-positive, microglia/macrophages 
were observed in PAs (19.9 ± 6.5%), similarly to DAs (20.9 ± 
9.9%).  Re-immunostaining of PA demonstrated that most 
Ki-67-positive, proliferating cells expressed Olig2, whereas 
GFAP or Iba1 expression in Ki-67-positive cells was less 
frequent (14.7 ± 13.7%, and 8.8 ± 13.6%) in a double 
immunostaining study.  Conversely, the percentage of 
Olig2-positive, proliferating cells in total Olig2-positive cells 
(7.2 ± 3.9%) was higher than that of Iba1-positive, proliferating 
cells in total Iba1-positive cells (0.9 ± 0.6%).  In conclusion, 
the present study found that PA consisted of numerous 
GFAP-negative cells, including Olig2-positive cells with high 
proliferation.  Semiquantitative analysis of Olig2 
immunohistochemistry in microcystic areas might therefore be 
useful for the differential diagnosis of PA and DA.  
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INTRODUCTION 
 
Pilocytic astrocytoma (PA) is a histologically well-characterized 
glial tumor.  In addition to characteristic biphasic pattern, such as 
compact and microcystic areas, there are sometimes 
oligodendroglioma-like areas that closely resemble 
oligodendrogliomas (ODs).  Several previous studies elucidated 
the immunohistochemical characterization of PA and there is little 
doubt that many Olig2-positive cells are distributed in PA.1,2  It is 
also well known that a high number of microglia/macrophages are 
consistently seen in gliomas.3-5  Sasaki et al.4 found that PA often 
contains high numbers of glucose transporter 5 (GLUT5)-positive 
microglia/macrophages when compared to other astrocytic and 
oligodendroglial tumors.  In addition, Klein et al.6 reported the 
highest levels of proliferating microglia in PA among astrocytic 
tumors.  However, despite the pronounced existence of Olig2- 
positive cells and microglia/macrophages in PA, there have been no 
detailed semiquantitative analysis of their proportion and 
proliferative activity.   
   Development of novel immunohistochemical markers such as 
the oligodendroglial marker Olig2 and microglial marker Iba1 has 
been pivotal in the diagnosis and research of brain tumors.  Olig2 
is a transcription factor that regulates the phenotype specification 
of cells of oligodendroglial lineage.7,8  Antibodies to Olig2 have 
demonstrated utility in paraffin sections for recognizing normal 
oligodendrocytes, oligodendrocytic tumors, and astrocytic tumors 
to some extent.1,9,10  Ionized calcium binding adaptor molecule 1, 
Iba1 mediates calcium signals in the monocytic lineage,11 and its 
antibody detects monocytic cells and macrophages including 
microglia.  Iba1 is expressed in both ramified and activated 
microglia.12  Its antigenicity is preserved in paraffin-embedded 
tissue sections after considerably long fixation.12  Previous studies 
have selected other microglial markers such as GLUT5,4 CD68 
(Ki-M1p),13 major histocompatibility complex (MHC) class II14 ; 
Iba1 has only been employed by a few studies.15  
   PA shows intense glial fibrillary acidic protein (GFAP) 
positivity in compact areas, but less so in microcystic areas.  
Furthermore, cells in oligodendroglioma-like area are not stained 
with GFAP antibody at all.  To solve the underlying mechanism of 
this heterogeneity, we elucidated the characteristics and distribution 
of GFAP- negative cells in PA by immunohistochemistry using 
Olig2 and Iba1 antibodies, and the mean labeling index (LI) of PAs 
was compared with that of diffuse astrocytomas (DAs), for which 
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differential diagnosis is sometimes needed.  In addition, we 
examined the proliferative activity of GFAP-, Iba1-, or 
Olig2-positive cells in PA by double or re-immunoperoxidase 
staining.  In a case with numerous Olig2-positive cells, 
fluorescence in situ hybridization (FISH) analysis was performed to 
exclude genetic changes frequently seen in OD.  Finally, we 
addressed tumor cell origin and growth mechanism in PA.   
  
 
MATERIALS AND METHODS 
 
Tissue specimens  
 
Tissue specimens were obtained from 37 cases of PAs (0-66 years 
old, mean age 24.2 ±21.2 years, 15 males and 22 females, 9 
supratentorial and 28 infratentorial) between 1980 and 2005 and 11 
cases of DAs (27-79 years old, mean age 43.5 ±14.5 years, 6 males 
and 5 females) between 1995 and 2004.  Informed consent was 
obtained from all patients whose tumor materials were used, and 
consent was also obtained from the local ethics committee.  
Patients underwent craniotomy and were pathologically diagnosed, 
having been identified from the pathology files of Gunma 
University Hospital and an affiliated hospital.  All histologic 
materials were reviewed according to the World Health 
Organization (WHO) classification,16,17 and selected when there 
were available paraffin blocks containing sufficient tissue for 
analysis. 
 
 
Immunohistochemistry 
 
Single immunoperoxidase staining 
Routine immunohistochemical examination using the 
biotin-streptavidin immunoperoxidase method (Histofine kit, 
Nichirei, Tokyo, Japan) was performed in formalin-fixed, paraffin 
embedded tissue sections.  Anti-GFAP (polyclonal, our own, 
1:5000)18, anti-Olig2-C (Olig2, polyclonal, our own, 1:5000)9, 
anti-Iba1 (polyclonal, Wako pure chemical industries, Japan, 1:250), 
and anti-Ki-67 (MIB-1, monoclonal, Dako, Glostrup, Denmark, 
1:50) were used.  For antigen retrieval before staining against 
Olig2, Iba1, and Ki-67, sections were autoclaved (121ºC, 5 min, in 
phosphate buffered saline pH7.4).   After visualization with 
diaminobenzidine (DAB), tissue sections were briefly 
counterstained with hematoxylin.  
   For semiquantitative analysis, LI of Olig2, Iba1, or Ki-67 was 
calculated as the percentage of positive cells in the total number of 
tumor cells in microscopic fields using the optical grid of a 40x 
objective lens.  We used sections where at least total 3000 cells 
positive for Olig2 or Iba1 and 2000 cells for Ki-67 could be 
counted, and LI was calculated in the area of maximal labeling.   
 
Double immunoperoxidase staining and re-immunoperoxidase 
staining 
First, 2 arbitrarily selected PA cases were analyzed by double 
immunostaining to examine the intracellular localization and the 
possibility of colocalization of these antigens.  Double 
immunostaining was performed according to the method reported 
previously 19 using DAB (brown) for the first antigen and 
4-chloro-1-naphthol (dark purple) for the second antigen. The 
combinations of antibodies were GFAP with Olig2, Olig2 with Iba1, 
and Iba1 with GFAP.  
   Second, double immunostaining for Ki-67 with GFAP, Ki-67 
with Iba1, and re-immunostaining for Ki-67 with Olig2 were 
performed in all PA cases to examine cellular proliferation.  The 
double immunostaining method was the same as mentioned above: 
Ki-67 for the first antigen and GFAP or Iba1 for the second antigen, 
respectively.  Briefly, for the re-immunostaining method, 
immediately after the first step using Ki-67 with the 4- chloro- 1- 
naphthol reaction, digital pictures were taken and saved on 
computer.  Thereafter, sections were treated with 0.1 M glycine- 
HCl buffer following a peroxidase reaction with DAB for the 
second antigen Olig2.  Hematoxylin counterstaining was per- 
formed on the re-stained sections, and they were compared with the 
digital pictures of the same microscopic fields taken beforehand. 
   For semiquantitative analysis, the first approach was applied to 
GFAP and Iba1 antibodies.  In sections where at least 100 
Ki-67-positive nuclei could be counted, LI was calculated in a way 
that the number of double-positive, proliferating cells was divided 
by the estimated number of total Ki-67-positive nuclei, and 
multiplied by 100.  The second approach was applied to Iba1 and 
Olig2 antibodies.  In sections where least 1000 Iba1- or 
Olig2-positive cells could be counted, LI was calculated in a way 
that the number of double- or re-positive, proliferating cells were 
divided by the estimated number of total Iba1- or Olig2-positive 
cells, and multiplied by 100.  
 
 
Fluorescence in situ hybridization (FISH)  
 
In a case of PA with numerous Olig2-positive cells, dual-probe 
hybridization was performed on paraffin-embedded 3-μm-thick 
tissue sections using a previously published FISH protocol.20  We 
used the 1p probe (RP11-260I13, 1p32) labeled with spectrum 
green and the 1q probe(RP11-184E11, 1q42) labeled with spectrum 
orange.  Signals of one hundred nonoverlapping nuclei were 
counted, and a ratio of green signals to orange signals of <0.8 was 
considered to constitute an allelic loss of 1p, as described 
previously.21   
 
 
Statistical analysis 
 
Mean LIs of PAs and DAs for Olig2-positive cells or Iba1-positive 
cells were calculated, and the Mann-Whitney U-test using JMP-IN 
5.1 software (SAS Institute Inc) was used to determine statistical 
significance. 
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Fig. 1  Histological and immunohistochemical 
findings in PA.  Compact areas and microcystic 
areas are marked with a single asterisk (*) and a 
double asterisk (**), respectively.  (A) 
Characteristic biphasic pattern seen on HE staining.  
(B) Long, bipolar tumor cells in the compact area 
show strong immunoreactivity for GFAP.  (C) 
Tumor cells with ambiguous processes in the 
microcystic area show strong reactivity for Olig2.  
(D) Nuclei of honeycomb cells in 
oligodendroglioma-like area (***) show strong 
immunoreactivity for Olig2.  (E) Iba1-positive 
microglia/macrophages are commonly distributed 
in microcystic area.  The inset shows a higher 
magnification of Iba1-positive, activated microglia.    
(F) A small number of Ki-67-positive proliferating 
cells (arrow) was mainly distributed in microcystic 
area.  Bars=50μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Pilocytic astrocytoma 
Immunoreactivity for GFAP, Olig2, and Iba1 was detected in all 37 
cases of PA.  A biphasic pattern was seen in 34 cases (92.0%) (Fig. 
1A).  A prominent reaction for GFAP was observed in compact, 
fiber-rich areas and only a weak reaction was observed in 
microcystic, loose areas (Fig. 1B).  Immunostaining for Olig2 was 
confined to nuclei, and was consistently present in cells with small 
nuclei and few flaccid processes in microcystic areas, but not 
significant in compact areas (Fig. 1C).  A large number of 
Olig2-positive cells was observed in tumor areas with honeycomb 
cells resembling OD (Fig. 1D).  Immunostaining for Iba1 was 
predominantly cytoplasmic and weakly nuclear.  Iba1-positive 
cells were commonly observed in microcystic areas, whereas only a 
minority of them was distributed in compact areas (Fig. 1E).  
Iba1-positive cells were morphologically compatible with activated 
microglia and macrophages (microglia/macrophages), including 
unipolar cells.  Ramified, resting microglia were scarcely seen in 
the tumor tissues.  Ki-67-positive cells were few and 
predominantly distributed in microcystic areas (Fig. 1F).  There 
was no correlation between the number and intensity of 
immunoreactivity and clinicopathological findings (patient age, sex 
and tumor location, data not shown).   
   Double immunoperoxidase staining using combinations of two 
antibodies between GFAP, Iba1, and Olig2 in a randomly selected 
two cases of PA demonstrated that there was no double labeling and 
that these antibodies were mutually exclusive (Fig. 2A-C).  
Double immunostaining showed brown nuclear staining for Ki-67 
with DAB and dark purple cytoplasmic staining for GFAP and Iba1 
with 4-chloro-1 naphtol (Fig. 2D, E).  In the re-immunoperoxidase 
staining method, almost all Ki-67-positive nuclei were also stained 
for Olig2 (Fig. 2F, G).    Double-positive proliferating cells were 
predominantly distributed in microcystic and oligodendroglioma 
-like areas, and to a lesser degree in compact areas.  
   Semiquantitative analyses of Olig2- and Iba1- positive cells 
were performed in 24 cases.  Thirteen cases that were small 
specimen without microcystic or oligodendroglioma-like areas 
were excluded.  The LI of GFAP-positive cells was not counted 
because of the complex arrangement of counterstained nuclei and 
GFAP-positive processes.  As a result, the mean LI for Olig2 was 
46.8 ±15.4% (SD) and the mean LI for Iba1 was 19.9 ± 6.9% (Fig. 
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3A).   
   Semiquantitative analyses of double immunostaining for GFAP 
with Ki-67 or Iba1 with Ki-67 was performed in 8 cases.  The 
mean Ki-67 LI was 3.6 ± 2.2% (Fig. 3B).  The mean LI of 
double-positive, proliferating cells in total Ki-67-positive, 
proliferating cells was 8.8± 13.6% for GFAP, and 14.7 ± 13.7% for 
Iba1, respectively (Fig. 3B).   The number of Ki-67-positive cells 
in serial sections of double immunostaining with GFAP or Iba1 was 
almost equal in each section.  However, the number of 
Ki-67-positive cells was fewer in re-immunostaining with Ki-67 
and Olig2 than in double immunostaining for GFAP or Iba1, 
probably due to weak staining in the former.  Thus, we could not 
perform comparative analysis of Olig2-positive cells in total 
proliferating cells. 
   Conversely, the mean LI of Iba1-positive, proliferating cells in 
total Iba1-positive cells was 0.9 ± 0.6% and that of Olig2-positive, 
proliferating cells in total Olig2-positive cells was 7.2 ± 4.0% (Fig. 
3C).  In each PA case, the individual LI of Olig2-positive, prolife- 
rating cells in total Olig2-positive cells tended to be higher than 
that of Iba1-positive, proliferating cells in total Iba1-positive cells. 
 
 
Diffuse astrocytoma 
Immunoreactivity for GFAP, Olig2, and Iba1 was detected in all 11 
DA cases.   Corresponding to the many processes of neoplastic 
astrocytes (Fig. 4A) the GFAP staining showed a diffuse, strong 
reaction (Fig. 4B), whereas Olig2- and Iba1- positive cells were 
also diffusely distributed but few in number (Fig. 4C, D).  Iba1- 
positive cells were morphologically compatible with microglia/ 
macrophages and almost all of them showed ramified, resting form. 
   All 11 DA cases had satisfactory tissue for semiquantitative 
analysis. The mean LI of Olig2 was 13.8 ± 7.8% and that of Iba1 
was 20.9 ± 9.9% (Fig. 3A).  
 
 
Statistical analysis 
 
For Olig2-positive cells, the mean LI in PA was significantly higher 
than that in DA (P<0.001).  In contrast, there was no significant 
difference in the mean LI of Iba1-positive cells between PA and DA 
(Fig. 3A). 
 
 
FISH  
 
In a case of PA with a high Olig2 LI (76.4%), 100 nuclei were 
counted and almost all nuclei had both 2 green and 2 orange signals.  
The ratio of green/orange signals was >0.8, and the case was 
judged to show no evidence of allelic loss of 1p (Fig. 5).  
 
Fig. 2  Double- or re-immunostaining in PA.  (A-C) Comparative double 
immunoperoxidase staining using GFAP (dark purple) with Olig2 (brown) 
(A), Olig2 (brown) with Iba1 (dark purple) (B), and Iba1 (brown) with 
GFAP (dark purple) (C) showed no double labeling.  (D,E) 
Double-positive, proliferating cells have brown nuclei for Ki-67 and dark 
purple cytoplasm for GFAP (D) or Iba1 (E) (arrows).  GFAP- negative, 
proliferating cells had only Ki-67-positive nuclei (arrowhead).   (F,G) 
Re-immunostaining in the same section using 4-chloro-1 naphtol for 
Ki-67(F) and DAB for Olig2 (G).  Almost all Ki-67-positive, dark purple 
nuclei were re-stained for Olig2 (arrows).  In re-stained section, 
Olig2-negative nuclei were counterstained with hematoxylin.  Bars=20μm. 
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DISCUSSION 
 
This study showed that Olig2-positive cells were the major cellular 
component of PA and mainly distributed in two areas: microcystic, 
textured loose areas and oligodendroglioma-like areas.  Previous 
reports1,2  have shown Olig2-positive cells in PA, however, this is 
the first semiquantitative analysis of Olig2-positive cells.  Our 
results indicate that the morphology and immunophenotype of 
Olig2-positive cells in oligodendroglioma-like areas were similar to 
those of oligodendroglioma cells, and that Olig2-positive cells in 
microcystic areas seemed to be compatible with so-called 
protoplasmic astrocytes with small nuclei and few flaccid processes.  
The mutual exclusivity of Olig2 and GFAP expression9 supports 
our finding that protoplasmic astrocytes with poor glial fibrils 
expressed Olig2 but not GFAP.  Furthermore, the following might 
explain Olig2 expression in protoplasmic astrocytes: (1) the 
transcriptional factor Olig2 appears in the oligodendrocyte lineage 
from oligodendrocyte precursors to adulthood, whereas it was 
reported that astrocytic lineage cells enigmatically express Olig2 in 
tumor environments,1,9,10 (2) Ohnishi et al.1 recently demonstrated 
that the proportion of Olig2-positive cells was high in protoplasmic 
astrocytomas.   
   Our semiquantitative analysis of Olig2-positive cells 
demonstrated a significant difference between PA and DA.  
Cytogenetical assessment such as allelic loss at 1p and 19q in OD 
is sometimes available for diagnosis of some gliomas.  However, 
PA is a clinicopathologically defined tumor, and cytogenetical 
assessment is not so useful for diagnosis.  For example, on 
analysis of genetic alteration, 64% of PA showed a normal 
karyotype, despite a tendency toward chromosomal gains, such as 
chromosomes 5 and 7.22  In addition, PA lacks definite molecular 
alterations23 such as the mutation or deletion of the TP53 gene and 
abnormal expression of EGFR observed in high grade glioma.24  
PA sometimes closely resembles DA and differential diagnosis is 
difficult.  Immunohistochemistry with glial markers such as GFAP 
is not so useful in this situation.  This study found high Olig2 
expression in microcystic and oligodendroglioma-like areas in PA 
and emphasizes the importance of semiquantitative analysis of 
Olig2 immunostaining in differential diagnosis of low grade 
astrocytomas.  
   We demonstrated that Olig2-positive cells constituted the main 
proliferating population in PA and that Olig2-positive cells had 
high proliferative potential.  The proportion of Olig2-positive, 
proliferating cells in total proliferating cells was estimated to be 
75% when LIs of GFAP- and Iba1-positive, proliferating cells were 
considered together.  However exact comparison between GFAP-, 
Iba1-, and Olig2-positive, proliferating cells in PA was impossible 
due to the different methods of immunohistochemistry.  Recently, 
progenitor cells have been generally believed to be closely  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3  Semiquantitative analysis of LIs using immunohistochemical 
markers.  (A) LIs of Olig2 and Iba1 between PA and DA.  The asterisk 
(*) indicates a significant difference of p<0.001 for PA versus DA in the 
immunostaining of Olig2.  There was no significant difference for Iba1.  
(B, C)  G, K, I, and O represent GFAP, Ki-67, Iba-1, and Olig2, 
respectively.  (B) Mean LI of Ki-67 alone (left), and mean LI of GFAP- 
(center), Iba1- (right), positive, proliferating cells in total Ki-67-positive, 
proliferating cells.  (C) Mean LI of Iba1-positive, proliferating cells in 
total Iba1-positive cells (left), and Olig2-positive, proliferating cells in total 
Olig2-positive cells (right).  Values are expressed as mean ± SD (%). 
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Fig. 4  Histological and immunohistochemical findings in DA.  (A) 
Typical area of fibrillary astrocytoma.  (B) A large number of processes of 
the tumor cells are diffusely and strongly stained with GFAP.  (C, D) 
Olig2- (C) or Iba1-(D) positive cells are also diffusely distributed but the 
number of positive cells is small.  Bars=50μm. 
 
 
associated with tumorigenesis and proliferation of brain tumors.25  
As reported previously, the high expression of PEN5, a sulfated 
polylactosamine carbohydrate epitope,26  and NG2 /PDGFαR27 in 
PA and OD indicate the possibility that both tumors are derived 
from common progenitor cells, oligodendrocyte progenitor cells 
(OPCs).    In addition, the strong expression of SOX10, an 
oligodendroglial specific transcriptional factor28, and the 
expression pattern of proteolipid protein or peripheral myelin 
protein(PMP)-2229 show some similarity between PA and 
oligodendroglial lineages.  Therefore, the Olig2-positive, 
proliferating cells observed in this study may derive from OPCs.  
In the present study, FISH analysis showed no LOH of 1p, 
suggesting that PA is not cytogenetically identical to OD.  As 
Shoshan et al.27 pointed out, both PA and OD can be neoplasms 
generated from OPCs, and they can give rise to neoplasms of 
clinically and pathologically distinctive phenotypes, probably as a 
result of the following: different environmental influences within 
the brain parenchyma, different acquired genetic alterations such as 
1p and 19q, and differential factors such as tumor location and host 
age. 
   Iba1-positive microglia/macrophages were a cellular 
component of PA, and they showed characteristic distribution and 
proliferative potential.  They represented approximately 20% of 
cells in PA, although the number of Iba1-positive cells was not 
significantly higher in PA than in DA.  Previous studies have 
shown that microglia/macrophages are highly abundant in 
gliomas,3,4 and Roggendorf et al.3 suggested a direct correlation 
between the grade of gliomas and the level of resident tumor 
microglia/macrophages.  Microglia/macrophages in gliomas are 
thought to be derived from various cells such as resident microglia, 
perivascular macrophages，and blood monocytes30 that can be 
stimulated by chemokines such as monocyte chemoattractant 
protein-1.31  In this study, Iba1-positive cells showed various 
morphological shapes, including monocyte-like cells with round 
cytoplasm and unipolar processes.  Due to the breakdown of the 
blood-brain barrier in gliomas, blood monocytes might be the most 
potent candidate for the origin of activated microglia/macrophages.   
   Abundant microglia/macrophages may play a role in the 
formation of the characteristic structure of PA.  LI of 
microglia/macrophages were not significantly higher in PA than 
that in DA, however the state of microglia was different; in PA they 
were distributed mainly in microcystic areas with a slightly 
activated morphology, whereas in DA they showed ramified form.   
In brain immune systems, the role of microglia/macrophages seems 
to be complex.  For example, microglia/macrophages can be 
neuroprotective/trophic or neurodestructive/toxic in inflammatory, 
degenerative, vascular or infective situations.32,33  
Microglia/macrophages could be recruited to the glioma to produce 
a number of cytokines, chemokines, and other mediators like 
growth factors.15,30  These mediators might then contribute to 
successful immune evasion, growth, and invasion of glioma cells.  
For example, microglia activated by glioblastoma cells produce 
metalloprotease-2, which supports tumor cell invasion into the 
matrix.34  In another study using a glioma tumor model,35 
microglia were a major source of prostaglandin E2 production 
through the expression of cyclooxygenase-2, and they might 
closely correlate with peritumoral edema in high grade glioma.  
Therefore, the unique background structures in microcystic areas 
(microcystic degeneration, myxoid matrix, edema) and 
macroscopic cystic formation in PA might be potentially caused by 
activated microglia/macrophages in addition to increased fluid 
transport by blood-brain barrier disturbance.36 
   The present study suggests that compact areas are long-standing 
areas and microcystic areas are developing areas in PA.  Compact 
areas mainly consisted of a population of piloid cells with strong 
GFAP expression.  These cells are a well-known characteristic 
feature of PA.  However, our results showed that this subset is a 
minor component; the LI of GFAP-positive cells was 
approximately 35%, as estimated from the LIs of Olig2 and Iba1.  
In addition, GFAP-positive cells scarcely had any proliferative 
activity.  This finding indicates that compact areas might be 
neoplastic but formed over a long time course.  This is supported 
by the following evidences16: (1) compact areas often include 
Rosenthal fibers, which are observed in chronic reactive gliosis, (2)  
A B 
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Fig. 5  Fluorescence in situ hybridization.  In this case, almost all nuclei 
had 2 red and 2 green signals, demonstrating no allelic loss of 1p. 
 
 
hair-like piloid cells are similar to reactive astrocytes in chronic 
pathologic lesions such as hypothalamus, cerebellum, or spinal 
cord.  On the other hand, we demonstrated that microcystic areas 
contain many proliferating tumor cells and many 
microglia/macrophages.  This result suggests that microcystic 
areas are responsible for tumor expansion by cellular proliferation, 
cystic change, and edema.  Further studies are required to assess 
the correlation between mature piloid cells of compact areas and 
maturing Olig2-positive cells of microcystic areas.  
   In conclusion, PA is a unique tumor consisting of cells with 
various glial immunophenotypes.  Olig2-positive cells which 
represent protoplasmic astrocytes, oligodendroglioma-like cells, 
and to some extent OPCs, are far more prevalent than 
GFAP-positive, piloid cells.  The numerical predominance and 
high proliferative activity of Olig2-positive cells in microcystic 
areas suggest their correlation with tumor development.  This 
study also suggests that Iba1-positive microglia/macrophages 
might be involved in tumor growth and microenvironmental 
formation.  Furthermore, semiquantitative analysis of Olig2 
immunohistochemistry in microcystic areas could be helpful for 
differential diagnosis of PA and DA when the histopathological 
diagnosis is problematic. 
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